WhiteFiber, through its subsidiary Enovum Data Centers, acquired two industrial properties in North Carolina for $60 million to expand its AI data center infrastructure. The sites, near its existing NC-1 campus, offer 120 acres and 500,000 sq ft of warehouse space, with an initial combined utility capacity of 60 MW, potentially growing to 200 MW within seven years. The company has received strong customer interest and aims to have the new capacity ready by late 2027, aligning development with customer contracts and financing. Operational challenges at NC-1 have delayed full capacity, but 35 MW of 40 MW is now active, with financing efforts ongoing.
WhiteFiber's recent acquisition of two North Carolina data center sites provides context for readers. For those following the Technology sector, 94 of 150 US stocks on Pluang rose while 53 fell as of Nov 04, 2026 03:41 WIB. Notable movers include CRDO at USD 152.37 with an 8.82% increase, GRAB at USD 3.11 up 8.74%, and AXTI at USD 52.12 gaining 8.13%.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
JELD-WEN Holding, Inc. reported a net loss of $17.2 million in Q3 2026, a significant improvement from a $367.6 million loss a year earlier, driven by tariff refunds, productivity gains, and cost reductions. Net revenues slightly declined by 1.4% to ...
Ethereum has achieved end-to-end formal verification of leanVM, a minimal zero-knowledge virtual machine designed to aggregate post-quantum signatures efficiently. This milestone is part of Ethereum's plan to transition its network to quantum-resista...
Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced its participation in several major healthcare conferences from November to December 2026. The company will engage in fireside chat...
